Literature DB >> 8511992

Immunoassay of pyridinoline crosslink excretion in normal adults and in Paget's disease.

P D Delmas1, E Gineyts, A Bertholin, P Garnero, F Marchand.   

Abstract

A new immunoassay (ELISA) based on an antiserum that preferentially recognizes the free form of the pyridinoline (Pyr) crosslink was used to assess the urinary excretion of Pyr in a large normal sample of the population comprising 236 men and 193 women 30-90 years of age. Urinary Pyr increased significantly with age in both sexes. In women Pyr was higher than in men (57 +/- 21 versus 46 +/- 17 nmol/mmol creatinine, p < 0.001), and the menopause was reflected by a mean 37% increase, from an average 43 to 59 nmol/mm creatinine (p < 0.001). In 52 patients with active Paget's disease of bone, Pyr excretion was markedly increased (206 +/- 160 nmol/mmol creatinine, p < 0.001 versus controls) and decreased by 71% after 3 days of IV treatment with the bisphosphonate pamidronate. Free Pyr measured by the ELISA and the total urinary excretion measured by HPLC were highly correlated both in normals (n = 74, r = 0.83, p < 0.001) and in Pagetic patients (n = 20, r = 0.93, p < 0.001). The mean intra- and interassay coefficients of variation of the ELISA were below 9 and 15%, respectively. It is concluded that this new convenient immunoassay of Pyr should be valuable for the clinical investigation of patients with osteoporosis and other metabolic bone diseases.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8511992     DOI: 10.1002/jbmr.5650080516

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  17 in total

1.  M-CSF neutralization and egr-1 deficiency prevent ovariectomy-induced bone loss.

Authors:  S Cenci; M N Weitzmann; M A Gentile; M C Aisa; R Pacifici
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

2.  Biochemical bone markers compared with bone density measurement by dual energy X-ray absorptiometry.

Authors:  J Lotz; D Steeger; G Hafner; W Ehrenthal; J Heine; W Prellwitz
Journal:  Calcif Tissue Int       Date:  1995-10       Impact factor: 4.333

3.  Biochemical markers of bone turnover: part I: biochemistry and variability.

Authors:  Markus J Seibel
Journal:  Clin Biochem Rev       Date:  2005-11

Review 4.  Bone loss in the elderly.

Authors:  J A Kanis; S Adami
Journal:  Osteoporos Int       Date:  1994       Impact factor: 4.507

5.  Appendicular bone density, biochemical markers of bone turnover and lifestyle factors in female teachers of Southern Italy.

Authors:  M Mariconda; M Pavia; A Colonna; I F Angelillo; O Marsico; F Sanzo; C Mancuso; C Milano
Journal:  Eur J Epidemiol       Date:  1997-12       Impact factor: 8.082

6.  Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats.

Authors:  R B Kimble; J L Vannice; D C Bloedow; R C Thompson; W Hopfer; V T Kung; C Brownfield; R Pacifici
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

7.  Rapid suppression of bone resorption and parathyroid hormone secretion by acute oral administration of calcium in healthy adult men.

Authors:  S Ortolani; A Scotti; R Cherubini
Journal:  J Endocrinol Invest       Date:  2003-04       Impact factor: 4.256

Review 8.  The two faces of growth: benefits and risks to bone integrity.

Authors:  A M Parfitt
Journal:  Osteoporos Int       Date:  1994-11       Impact factor: 4.507

9.  Variable efficacy of bone remodeling biochemical markers in the management of patients with Paget's disease of bone treated with tiludronate.

Authors:  C de la Piedra; A Rapado; E M Díaz Diego; M A Díaz Martín; C Aguirre; E López Gavilanes; M Díaz Curiel
Journal:  Calcif Tissue Int       Date:  1996-08       Impact factor: 4.333

10.  Urinary biochemical markers for bone resorption during the menstrual cycle.

Authors:  I Gorai; O Chaki; M Nakayama; H Minaguchi
Journal:  Calcif Tissue Int       Date:  1995-08       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.